Clinical characteristics of cytomegalovirus infection in rheumatic diseases: Multicentre survey in a large patient population

Rheumatology

Volumn 47, Issue 9, 2008, Pages 1373-1378

  Takizawa, Y ^a   Inokuma, S ^a,b   Tanaka, Y ^a,c   Saito, K ^c   Atsumi, T ^d   Hirakata, M ^e   Kameda, H ^f   Hirohata, S ^g,h   Kondo, H ^h   Kumagai, S ⁱ  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f Department of Gastroenterology   (Japan)

^g TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclophosphamide; Cytomegalovirus; Cytomegalovirus antigenaemia count; Immunosuppressive therapy; Lymphopenia; Old age; Pulsed methylprednisolone; Rheumatic diseases

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BEHCET DISEASE; BIOPSY; BLOOD SAMPLING; CHILD; COMORBIDITY; COUGHING; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DISEASE DURATION; DISEASE MARKER; DRUG EFFICACY; DRUG PULSE THERAPY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOCHEZIA; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATIC DISEASE; SEX RATIO; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL; CHILD; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS;

EID: 50849091596     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken231     Document Type: Article

References (32)

1. Wasko MC. Comorbid conditions in patients with rheumatic diseases: An update. Curr Opin Rheumatol 2004;16:109-13.
2. Watts RA, Scott DG. Epidemiology of the vasculitides. Curr Opin Rheumatol 2003;15:11-6.
3. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528-34.
4. Koszinowski UH, DelVal M, Reddehase MJ. Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 1990;154:189-220.
5. Preiksaitis JK, Brennan DC, Fishman J et al. Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005;5:218-27.
6. Bek B, Boeckh M, Lepenies L et al. High level sensitivity of quantitative pp65 cytomegalovirus(CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996;34:457-9.
7. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992;80:1358-64.
8. Mori T, Kameda H, Ogawa H et al. Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. J Rheumatol 2004;31:1349-51.
9. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Arthritis Rheum 1995;38:1492-9.
10. Ikura Y, Matsuo T, Ogami M et al. Cytomegalovirus-associated pancreatitis in a patient with systemic lupus erythematosus. J Rheumatol 2000;27:2715-7.
11. Bulpitt KJ, Brahn E. Systemic lupus erythematosus and concurrent cytomegalovirus vasculitis: Diagnosis by antemortem skin biopsy. J Rheumatol 1989;16:677-80.
12. Garcia-Porrua C, Gonzalez-Gay MA, Perez de Llano LA et al. Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus. Scand J Rheumatol 1998;27:465-6.
13. Aglas F, Riner F, Hermann J et al. Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis. Arthritis Rheum 1995;38:291-2.
14. Fraenkel G, Ross B, Wong HC. Cytomegalovirus retinitis in a patient with rheumatoid arthritis being treated with combination immunosuppressive therapy. Retina 1995;15:169-70.
15. Boeckh M, Boivin G. Quantification of cytomegalovirus: Methodologic aspects and clinical applications. Clin Microbiol Rev. 1998;11:533-4.
16. Dodt KK, Jacobsen PH, Hofmann B et al. Development of cytomegalovirus(CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997;11:F21-8.
17. Gema G, Zipeto D, Parea M et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991;164:488-98.
18. Grefte JM, van der Gun BT, Schmolke S et al. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 1992;73:2923-32.
19. Grossi P, Minoli L, Percivalle E et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995;59:847-51.
20. Revello MG, Percivalle E, DiMatteo A et al. Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. J Gen Virol 1992;73:437-42.
21. van den Berg AP, Klompmaker FI, Hangoma EB et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation, J Infect Dis 1991;164:265-70.
22. van den Berg AP, van der Rij W, van Son WJ et al. Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplanton. Transplant Int 1992;5:101-6.
23. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope Stanford Syntex Cytomegalovirus Study Group. N Engl J Med 1991;324:1005-111.
24. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43:869-80.
25. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes 2003;10:12-6.
26. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases. Basic and clinical correlates. Ann Intern Med 1993;119:1198-208.
27. Auphan N, DiDonato JA, Rosette C et al. Immunosuppression by glucocorticoids. Inhibition of NF-kappa B activity through induction of IkB synthesis. Science 1995;270:286-90.
28. Neumann M, Naumann M. Beyond IkappaBs: Alternative regulation of NF-kappaB activity. FASEB J 2007;21:2642-54.
29. Connors M, Kovacs JS, Krevat S et al. HIV infection induces changes in CD4+ T cell phenotypes and depletions within the CD4+ T cell repertoire that are not immediately restored by antiretroviral or immune-base therapy. Nat Med 1997;3:533-40.
30. Weekes MP, Wills MR, Sissons JG et al. Long-term stable expanded human CD4+ T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations. J Immunol 2004;173:5843-51.
31. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867-74.
32. Ho AAM. Observations from transplantation contributing to the understanding of pathogenesis of CMV infection. Transplant Proc 1991;23:104-9.